Fair Value Measurements and Financial Instruments (Contingent Consideration Liabilities Reconciliation) (Details) - USD ($)
$ in Millions |
1 Months Ended |
12 Months Ended |
Oct. 31, 2014 |
Jan. 02, 2016 |
Jan. 03, 2015 |
Dec. 28, 2013 |
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Change in fair value of contingent consideration |
|
$ (87)
|
$ 22
|
$ 1
|
| Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Beginning balance |
|
50
|
195
|
0
|
| Initial fair value measurement of contingent consideration |
|
155
|
|
188
|
| Change in fair value of contingent consideration |
|
(87)
|
22
|
1
|
| Foreign currency translation |
|
|
(12)
|
6
|
| Payment of contingent consideration |
|
|
(155)
|
|
| Liabilities assumed from Thoratec acquisition |
|
33
|
|
|
| Ending balance |
|
151
|
50
|
195
|
| Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Spinal Modulation [Member] |
|
|
|
|
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Beginning balance |
|
0
|
0
|
0
|
| Initial fair value measurement of contingent consideration |
|
155
|
|
0
|
| Change in fair value of contingent consideration |
|
(33)
|
0
|
0
|
| Foreign currency translation |
|
|
0
|
0
|
| Payment of contingent consideration |
|
|
0
|
|
| Liabilities assumed from Thoratec acquisition |
|
0
|
|
|
| Ending balance |
|
122
|
0
|
0
|
| Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Endosense S.A. [Member] |
|
|
|
|
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Beginning balance |
|
0
|
139
|
0
|
| Initial fair value measurement of contingent consideration |
|
0
|
|
132
|
| Change in fair value of contingent consideration |
|
0
|
28
|
1
|
| Foreign currency translation |
|
|
(12)
|
6
|
| Payment of contingent consideration |
$ (155)
|
|
(155)
|
|
| Liabilities assumed from Thoratec acquisition |
|
0
|
|
|
| Ending balance |
|
0
|
0
|
139
|
| Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Nanostim [Member] |
|
|
|
|
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Beginning balance |
|
50
|
56
|
0
|
| Initial fair value measurement of contingent consideration |
|
0
|
|
56
|
| Change in fair value of contingent consideration |
|
(48)
|
(6)
|
0
|
| Foreign currency translation |
|
|
0
|
0
|
| Payment of contingent consideration |
|
|
0
|
|
| Liabilities assumed from Thoratec acquisition |
|
0
|
|
|
| Ending balance |
|
2
|
50
|
56
|
| Contingent Consideration Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Thoratec [Member] |
|
|
|
|
| Contingent Consideration Liability [Roll Forward] |
|
|
|
|
| Beginning balance |
|
0
|
0
|
0
|
| Initial fair value measurement of contingent consideration |
|
0
|
|
0
|
| Change in fair value of contingent consideration |
|
(6)
|
0
|
0
|
| Foreign currency translation |
|
|
0
|
0
|
| Payment of contingent consideration |
|
|
0
|
|
| Liabilities assumed from Thoratec acquisition |
|
33
|
|
|
| Ending balance |
|
$ 27
|
$ 0
|
$ 0
|